Zura Bio expands clinical pipeline as quarterly losses widen
The biotechnology company reported a net loss of $26.3 million for the second quarter ended June 30, 2026.
Zura Bio (ZURA), a clinical-stage biotechnology company, reported a net loss of $26.3 million for the second quarter ended June 30, 2026.
The result reflects an acceleration in spending as the company advances its lead clinical programs. The net loss was $0.21 a share, compared to a loss of $16.0 million, or $0.17 a share, in the second quarter of 2025.
Research and development expenses rose to $20.7 million from $8.7 million in the prior-year period. The increase was due to the advancement of Phase 2 clinical programs for tibulizumab. General and administrative expenses decreased to $8.6 million from $9.4 million in the second quarter of 2025, primarily due to lower professional fees.
Zura Bio expanded the scope of its tibulizumab program by selecting polymyalgia rheumatica as a third indication. The company plans to begin a Phase 2 study, known as NEXUS-PMR, by the end of 2026.
Enrollment concluded for two other Phase 2 tibulizumab studies, with both exceeding initial targets. The TibuSHIELD study for hidradenitis suppurativa enrolled 247 participants, while the TibuSURE study for systemic sclerosis enrolled 91 participants.
The company now expects topline data for TibuSHIELD in the fourth quarter of 2026. Data for TibuSURE is expected in the first half of 2027.
Cash and cash equivalents increased to $205.1 million as of June 30, 2026. This follows a balance of $109.4 million reported as of December 31, 2025.